Akihiro Tsuboi Selected Research

Protein Subunit Vaccines

2/2022	WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine.
1/2022	Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.
1/2022	Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer.
1/2021	Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies.
1/2021	Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.
9/2020	Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT.
11/2018	Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides.
1/2018	WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.
1/2017	Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
12/2016	Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Akihiro Tsuboi Research Topics

Disease

69	Neoplasms (Cancer) 06/2022 - 05/2002
22	Leukemia 09/2016 - 08/2002
16	Wilms Tumor (Wilm's Tumor) 06/2022 - 01/2007
9	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 05/2002
9	Lung Neoplasms (Lung Cancer) 12/2016 - 07/2002
7	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2022 - 05/2002
7	Glioma (Gliomas) 01/2022 - 04/2010
7	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 05/2008
7	Residual Neoplasm 01/2017 - 03/2003
6	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2017 - 07/2003
5	Erythema 11/2009 - 07/2003
4	Multiple Myeloma 01/2022 - 12/2007
4	Hypersensitivity (Allergy) 09/2016 - 09/2009
4	Breast Neoplasms (Breast Cancer) 05/2010 - 07/2003
3	Disease Progression 01/2022 - 05/2002
3	Leukopenia 06/2007 - 07/2003
2	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 04/2006
2	Melanoma (Melanoma, Malignant) 08/2019 - 03/2012
2	Brain Neoplasms (Brain Tumor) 06/2015 - 07/2009
2	Pancreatic Neoplasms (Pancreatic Cancer) 05/2014 - 02/2014
2	Fibrosarcoma 05/2014 - 04/2006
2	Adenocarcinoma 07/2004 - 08/2003
2	Graft vs Host Disease (Graft-Versus-Host Disease) 04/2003 - 07/2002
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2003 - 05/2002
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 03/2003 - 05/2002
1	Sarcoma (Soft Tissue Sarcoma) 02/2022
1	Ascites 01/2022
1	Inflammation (Inflammations) 01/2022
1	Lymphopenia (Lymphocytopenia) 06/2015
1	Myeloid Leukemia (Leukemia, Myelocytic) 01/2015
1	Prostatic Neoplasms (Prostate Cancer) 05/2014
1	Stomach Neoplasms (Stomach Cancer) 05/2014
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2014
1	Colonic Neoplasms (Colon Cancer) 05/2014
1	Squamous Cell Carcinoma of Head and Neck 05/2014

Drug/Important Bio-Agent (IBA)

49	Peptides (Polypeptides)IBA 02/2022 - 08/2002
31	AntigensIBA 06/2022 - 08/2002
29	WT1 ProteinsIBA 06/2022 - 05/2002
18	VaccinesIBA 06/2022 - 05/2002
18	Protein Subunit VaccinesIBA 02/2022 - 09/2004
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2004
9	Cancer VaccinesIBA 02/2022 - 04/2006
9	EpitopesIBA 02/2022 - 01/2008
9	HLA-A Antigens (HLA-A)IBA 11/2009 - 12/2002
7	Immunoglobulin G (IgG)IBA 02/2022 - 05/2002
6	AntibodiesIBA 02/2022 - 05/2002
6	Messenger RNA (mRNA)IBA 07/2015 - 07/2003
5	HLA-A*24:02 antigenIBA 01/2022 - 12/2012
4	Monoclonal AntibodiesIBA 01/2022 - 01/2012
4	Neoplasm Antigens (Tumor Antigens)IBA 01/2021 - 07/2003
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2018 - 03/2010
4	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 10/2004 - 03/2003
3	Immunoglobulin M (IgM)IBA 02/2022 - 05/2002
3	LigandsIBA 01/2021 - 12/2007
3	Protein Isoforms (Isoforms)IBA 01/2015 - 04/2006
3	Monatide (IMS 3015)IBA 03/2012 - 07/2003
3	HLA-A*02:01 antigenIBA 03/2012 - 12/2005
3	DNA (Deoxyribonucleic Acid)IBA 08/2003 - 07/2002
2	HLA Antigens (Human Leukocyte Antigens)IBA 02/2022 - 11/2009
2	Surface Antigens (Surface Antigen)IBA 01/2022 - 12/2017
2	ProteomeIBA 01/2022 - 12/2017
2	Histocompatibility Antigens Class IIBA 01/2022 - 01/2012
2	CytokinesIBA 05/2020 - 04/2013
2	Cell Wall SkeletonIBA 08/2019 - 07/2004
2	Complementary DNA (cDNA)IBA 12/2016 - 07/2004
2	Small Interfering RNA (siRNA)IBA 12/2016 - 05/2014
2	Temozolomide (Temodar)FDA LinkGeneric 06/2015 - 05/2010
2	Gemcitabine FDA Link 02/2014 - 05/2007
2	InterferonsIBA 12/2012 - 01/2012
2	Immunoglobulin IsotypesIBA 05/2007 - 05/2002
2	Tumor Biomarkers (Tumor Markers)IBA 09/2004 - 01/2004
1	C-Reactive ProteinIBA 01/2022
1	Serum AlbuminIBA 01/2022
1	Glucose (Dextrose)FDA LinkGeneric 09/2020
1	IntegrinsIBA 12/2017
1	Biomarkers (Surrogate Marker)IBA 12/2016
1	Syndecan-4IBA 12/2016
1	Immunomodulating AgentsIBA 02/2016
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2016
1	Neuraminidase (Sialidase)IBA 01/2016
1	HLA-DRB1*04 antigenIBA 03/2015
1	Minor Histocompatibility AntigensIBA 10/2014
1	Peptide Elongation Factors (Elongation Factor)IBA 05/2014
1	ImmunosorbentsIBA 05/2014
1	EnzymesIBA 05/2014
1	Peptide Elongation Factor 2 (EF-2)IBA 05/2014
1	AutoantibodiesIBA 05/2014
1	Granzymes (Granzyme)IBA 04/2013
1	PerforinIBA 04/2013
1	HLA-DPB1 antigen (HLA DPB1)IBA 04/2013
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2012

Therapy/Procedure

50	Immunotherapy 06/2022 - 05/2002
20	Therapeutics 01/2022 - 04/2006
5	Drug Therapy (Chemotherapy) 01/2022 - 05/2007
3	Hematopoietic Stem Cell Transplantation 01/2017 - 10/2014
2	Radiotherapy 06/2015 - 05/2010
2	Intradermal Injections 01/2009 - 07/2004
1	Withholding Treatment 06/2021
1	Injections 06/2015
1	Aftercare (After-Treatment) 02/2014